RAPT Therapeutics Inc. Overview

RAPT Therapeutics, Inc., a pharmaceutical company based in South San Francisco, United States, specializes in immunology, small molecule drug discovery, and computational biology services. The company focuses on developing treatments for cancer and allergic inflammatory diseases. RAPT Therapeutics operates globally and is listed on the Nasdaq stock exchange.

Financial Snapshot

As of July 13, 2025, RAPT Therapeutics’ stock closed at $8.72. The company’s market capitalization stands at approximately $142.54 million. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $30.08 on July 16, 2024, and a 52-week low of $5.664 on May 14, 2025. The price-to-earnings ratio is currently -0.439373, indicating that the company is not yet profitable.

Business Focus

RAPT Therapeutics is dedicated to combating cancer and allergic inflammatory diseases through its specialized services in immunology, small molecule drug discovery, and computational biology. The company’s innovative approach aims to advance therapeutic solutions in these critical areas of healthcare.

For more information about RAPT Therapeutics’ offerings and initiatives, interested parties can visit their website at www.rapt.com .